Galenica


Market share gains drive a strong H1

09/08/19 -"Galenica reported H1 19 revenue of CHF 1.6bn, above both consensus and our estimates. The strong growth in health and beauty was partly offset by slower growth in services. Adjusted EBIT came in at ..."

Pages
40
Language
English
Published on
09/08/19
You may also be interested by these reports :
14/10/19
FY18/19 earnings were negatively impacted by various non-recurring items. Nevertheless, we still believe in the company’s development potential due ...

14/10/19
Due to various one-off charges, such as the accounting adjustment to the fair value of earn outs amounting to €6.4m and the net loss related to the ...

11/10/19
Slightly more than a week ago, we mentioned that Health stocks (ex Pharma) were way too expensive and that their outperformance was starting to erode ...

11/10/19
While organic sales growth was in-line in Q3 19, the operating margin slumped by 80bp, weighed down by increasing headwinds from trade tariffs, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO